81 related articles for article (PubMed ID: 15623809)
1. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
Xiang AH; Peters RK; Kjos SL; Ochoa C; Marroquin A; Goico J; Tan S; Wang C; Azen SP; Liu CR; Liu CH; Hodis HN; Buchanan TA
J Clin Endocrinol Metab; 2005 Apr; 90(4):1986-91. PubMed ID: 15623809
[TBL] [Abstract][Full Text] [Related]
2. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
3. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Xiang AH; Hodis HN; Kawakubo M; Peters RK; Kjos SL; Marroquin A; Goico J; Ochoa C; Liu CR; Liu CH; Buchanan TA
Atherosclerosis; 2008 Jul; 199(1):207-14. PubMed ID: 18054942
[TBL] [Abstract][Full Text] [Related]
4. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.
Zheng L; Hodis HN; Buchanan TA; Li Y; Mack WJ
Am J Cardiol; 2007 Apr; 99(7):956-60. PubMed ID: 17398191
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
7. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
Hodis HN; Mack WJ; Zheng L; Li Y; Torres M; Sevilla D; Stewart Y; Hollen B; Garcia K; Alaupovic P; Buchanan TA
Diabetes Care; 2006 Jul; 29(7):1545-53. PubMed ID: 16801577
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
Xiang AH; Peters RK; Kjos SL; Goico J; Ochoa C; Marroquin A; Tan S; Hodis HN; Azen SP; Buchanan TA
J Clin Endocrinol Metab; 2004 Jun; 89(6):2846-51. PubMed ID: 15181067
[TBL] [Abstract][Full Text] [Related]
9. Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect.
Dogan S; Plantinga Y; Crouse JR; Evans GW; Raichlen JS; O'Leary DH; Palmer MK; Grobbee DE; Bots ML;
J Hypertens; 2011 Nov; 29(11):2181-93. PubMed ID: 21918474
[TBL] [Abstract][Full Text] [Related]
10. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Buchanan TA; Xiang AH; Peters RK; Kjos SL; Marroquin A; Goico J; Ochoa C; Tan S; Berkowitz K; Hodis HN; Azen SP
Diabetes; 2002 Sep; 51(9):2796-803. PubMed ID: 12196473
[TBL] [Abstract][Full Text] [Related]
11. Effect of short term intensive multitherapy on carotid intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus.
Guo LX; Pan Q; Wang XX; Li H; Zhang LN; Chi JM; Wang Y
Chin Med J (Engl); 2008 Apr; 121(8):687-90. PubMed ID: 18701019
[TBL] [Abstract][Full Text] [Related]
12. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Buchanan TA; Xiang AH; Peters RK; Kjos SL; Berkowitz K; Marroquin A; Goico J; Ochoa C; Azen SP
Diabetes; 2000 May; 49(5):782-8. PubMed ID: 10905487
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
[TBL] [Abstract][Full Text] [Related]
14. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
Snitker S; Watanabe RM; Ani I; Xiang AH; Marroquin A; Ochoa C; Goico J; Shuldiner AR; Buchanan TA;
Diabetes Care; 2004 Jun; 27(6):1365-8. PubMed ID: 15161789
[TBL] [Abstract][Full Text] [Related]
15. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
[TBL] [Abstract][Full Text] [Related]
16. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
17. Early onset of subclinical atherosclerosis in women with gestational diabetes mellitus.
Tarim E; Yigit F; Kilicdag E; Bagis T; Demircan S; Simsek E; Haydardedeoglu B; Yanik F
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):177-82. PubMed ID: 16435313
[TBL] [Abstract][Full Text] [Related]
18. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus.
Polonsky T; Mazzone T; Davidson M
Trends Cardiovasc Med; 2009 Apr; 19(3):94-9. PubMed ID: 19679266
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
20. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Prigeon RL; Kahn SE; Porte D
J Clin Endocrinol Metab; 1998 Mar; 83(3):819-23. PubMed ID: 9506734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
